SCHEDULE: FMR LLC and Abigail P. Johnson Disclose 12.3% Stake in Ocular Therapeutix Inc.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 12.3% of Ocular Therapeutix Inc.'s common stock as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson reported beneficial ownership of 19,608,170.74 shares of Ocular Therapeutix Inc. common stock.
• This aggregate amount represents 12.3% of the total outstanding common stock of Ocular Therapeutix Inc.
• FMR LLC holds sole voting power over 19,601,208.00 shares and sole dispositive power over 19,608,170.74 shares.
• Abigail P. Johnson holds sole dispositive power over 19,608,170.74 shares, with no sole or shared voting power directly.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant institutional ownership stake. While not directly indicative of company performance, a large stake by a prominent investment firm like FMR LLC can be viewed as a vote of confidence, suggesting a neutral to slightly positive sentiment from an investor perspective.

Positives

• A Schedule 13G filing primarily discloses beneficial ownership and does not typically contain information about the issuer's operational or financial performance that would be categorized as "positives."

Negatives

• A Schedule 13G filing primarily discloses beneficial ownership and does not typically contain information about the issuer's operational or financial performance that would be categorized as "negatives."

Risks

• A Schedule 13G filing is a disclosure of beneficial ownership and does not typically detail specific risks related to the issuer's business operations or financial condition.

Future Outlook

A Schedule 13G filing is a disclosure of beneficial ownership and does not provide forward-looking statements or guidance from the issuer.

Management Comments

• This filing is made by an institutional investor (FMR LLC) and an individual (Abigail P. Johnson) regarding their beneficial ownership, not by the issuer's management commenting on company operations.

Industry Context

This Schedule 13G filing indicates a significant institutional investment in Ocular Therapeutix Inc. by FMR LLC, a major asset management firm. Such disclosures are routine regulatory requirements for investors acquiring more than 5% of a company's shares, providing transparency into large ownership stakes within the market.

Comparison to Industry Standards

• A Schedule 13G filing reports a specific beneficial ownership stake and does not provide data for comparison to industry-wide operational or financial benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• A Schedule 13G filing is a disclosure of beneficial ownership and does not typically contain information about legal proceedings or regulatory matters concerning the issuer.

Related Party Transactions

• Abigail P. Johnson is a Director, Chairman, and Chief Executive Officer of FMR LLC.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners (49% voting power) of Series B voting common shares of FMR LLC.
• The Johnson family group and other Series B shareholders have entered into a shareholders' voting agreement, under which all Series B voting common shares will be voted in accordance with the majority vote, potentially deeming them a controlling group with respect to FMR LLC under the Investment Company Act of 1940.
• The filing reflects securities beneficially owned by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters'), while disaggregating beneficial ownership of certain other companies as per SEC guidance.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like FMR LLC may be perceived positively, potentially increasing investor confidence and attracting further investment interest in Ocular Therapeutix Inc.

Next Steps

• A Schedule 13G filing is a disclosure of current beneficial ownership and does not typically outline future actions or milestones for the issuer or the reporting entity beyond regulatory compliance.

Key Dates

Keywords

Ocular Therapeutix Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management